Chimerix (CMRX) News Today $8.51 +0.01 (+0.12%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$8.52 +0.01 (+0.06%) As of 03/25/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Rosalind Advisors Inc. Invests $10.61 Million in Chimerix, Inc. (NASDAQ:CMRX)Rosalind Advisors Inc. purchased a new stake in Chimerix, Inc. (NASDAQ:CMRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 3,050,000 shares of the biopharmaceutical company's stock, valued at approximately $10,614,000. ChimMarch 23 at 5:48 AM | marketbeat.comChimerix (NASDAQ:CMRX) Now Covered by StockNews.comStockNews.com started coverage on Chimerix in a report on Sunday. They issued a "hold" rating on the stock.March 23 at 2:10 AM | marketbeat.comChimerix (NASDAQ:CMRX) Releases Earnings Results, Beats Estimates By $0.01 EPSChimerix (NASDAQ:CMRX - Get Free Report) released its earnings results on Friday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million.March 22, 2025 | marketbeat.comChimerix reports Q4 EPS (25c), consensus (28c)March 22, 2025 | markets.businessinsider.comChimerix Reports Fourth Quarter and Year End 2024 Financial ResultsMarch 21, 2025 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Acquires 84,801 Shares of Chimerix, Inc. (NASDAQ:CMRX)Connor Clark & Lunn Investment Management Ltd. increased its stake in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 24.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 429,513 shares ofMarch 20, 2025 | marketbeat.comChimerix (NASDAQ:CMRX) Hits New 52-Week High - Should You Buy?Chimerix (NASDAQ:CMRX) Sets New 52-Week High - Time to Buy?March 18, 2025 | marketbeat.comChimerix, Inc. (NASDAQ:CMRX) Holdings Reduced by Monaco Asset Management SAMMonaco Asset Management SAM trimmed its position in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 33.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,820,792 shares of the biopharmaceutical company's stock after selliMarch 15, 2025 | marketbeat.comChimerix (NASDAQ:CMRX) Earns Hold Rating from Analysts at StockNews.comStockNews.com assumed coverage on shares of Chimerix in a research note on Saturday. They issued a "hold" rating on the stock.March 15, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of ShareholdersMarch 14, 2025 | morningstar.comChimerix (NASDAQ:CMRX) Sets New 12-Month High - Here's What HappenedChimerix (NASDAQ:CMRX) Hits New 12-Month High - Here's WhyMarch 13, 2025 | marketbeat.comCHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRXMarch 10, 2025 | businesswire.comChimerix (NASDAQ:CMRX) Sees Strong Trading Volume - Should You Buy?Chimerix (NASDAQ:CMRX) Sees Strong Trading Volume - Time to Buy?March 8, 2025 | marketbeat.comChimerix (NASDAQ:CMRX) Upgraded at Jones TradingJones Trading upgraded shares of Chimerix to a "hold" rating in a report on Thursday.March 8, 2025 | marketbeat.comCMRX Stock Surges on JAZZ Acquisition BidMarch 8, 2025 | finance.yahoo.comCMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. ...March 7, 2025 | gurufocus.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comCMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to ShareholdersMarch 7, 2025 | globenewswire.comJefferies Financial Group Reaffirms "Hold" Rating for Chimerix (NASDAQ:CMRX)Jefferies Financial Group reissued a "hold" rating and issued a $8.50 target price (down from $10.00) on shares of Chimerix in a research report on Wednesday.March 6, 2025 | marketbeat.comPromising Small Cap Stocks To Follow Now - March 5thChimerix, AltC Acquisition, Visionary, Visionary, and Gorilla Technology Group are the five Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small cap stocks are shares of companies with relatively small market capitalizations, generally ranging from around US$300 milMarch 6, 2025 | marketbeat.comChimerix downgraded to Hold from Buy at JonesResearchMarch 6, 2025 | markets.businessinsider.comWedbush Reiterates Neutral Rating for Chimerix (NASDAQ:CMRX)Wedbush restated a "neutral" rating and set a $8.55 target price (up from $7.00) on shares of Chimerix in a research report on Wednesday.March 6, 2025 | marketbeat.comChimerix's (CMRX) Neutral Rating Reaffirmed at HC WainwrightHC Wainwright restated a "neutral" rating and set a $8.55 price target (down previously from $11.00) on shares of Chimerix in a research note on Wednesday.March 6, 2025 | marketbeat.comChimerix (NASDAQ:CMRX) Shares Gap Up - Time to Buy?Chimerix (NASDAQ:CMRX) Shares Gap Up - Should You Buy?March 6, 2025 | marketbeat.comChimerix downgraded to Neutral from Outperform at WedbushMarch 6, 2025 | markets.businessinsider.comChimerix (NASDAQ:CMRX) Hits New 12-Month High - What's Next?Chimerix (NASDAQ:CMRX) Reaches New 12-Month High - Time to Buy?March 6, 2025 | marketbeat.comNorth Carolina drugmaker sold in $935M dealMarch 6, 2025 | bizjournals.comCMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to ShareholdersMarch 6, 2025 | tmcnet.comChimerix downgraded to Neutral from Buy at H.C. WainwrightMarch 6, 2025 | markets.businessinsider.comChimerix downgraded to Hold from Buy at JefferiesMarch 6, 2025 | msn.comHC Wainwright & Co. Downgrades Chimerix (CMRX)March 6, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRXMarch 5, 2025 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of ShareholdersMarch 5, 2025 | prnewswire.comJazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer PipelineMarch 5, 2025 | benzinga.comJazz Pharmaceuticals to buy Chimerix for $935 millionMarch 5, 2025 | reuters.comJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology PortfolioMarch 5, 2025 | globenewswire.comJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology PortfolioMarch 5, 2025 | prnewswire.comChimerix (CMRX) Projected to Post Quarterly Earnings on ThursdayChimerix (NASDAQ:CMRX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comWedbush Has Optimistic Outlook of Chimerix FY2025 EarningsChimerix, Inc. (NASDAQ:CMRX - Free Report) - Analysts at Wedbush upped their FY2025 earnings per share estimates for shares of Chimerix in a research report issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.03) per shareFebruary 21, 2025 | marketbeat.comChimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma PatientsFebruary 20, 2025 | seekingalpha.comWhat is Wedbush's Forecast for Chimerix FY2028 Earnings?Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Analysts at Wedbush upped their FY2028 earnings estimates for Chimerix in a research report issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of $0.58 per share for tFebruary 20, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Chimerix (NASDAQ:CMRX)Wedbush reissued an "outperform" rating and set a $7.00 price target (up from $6.00) on shares of Chimerix in a research note on Tuesday.February 19, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Chimerix (NASDAQ:CMRX)HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Chimerix in a report on Tuesday.February 19, 2025 | marketbeat.comChimerix (NASDAQ:CMRX) Given "Outperform" Rating at WedbushWedbush reiterated an "outperform" rating and set a $7.00 target price (up previously from $6.00) on shares of Chimerix in a research note on Tuesday.February 19, 2025 | marketbeat.comChimerix stock rises on FDA priority review for dordaviproneFebruary 19, 2025 | au.investing.comChimerix Shares Touch 52-Week High on Speedy FDA Review of Brain Tumor TreatmentFebruary 19, 2025 | marketwatch.comChimerix’s NDA for dordaviprone accepted by FDAFebruary 19, 2025 | markets.businessinsider.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 18, 2025 | globenewswire.comValeo Financial Advisors LLC Buys 64,420 Shares of Chimerix, Inc. (NASDAQ:CMRX)Valeo Financial Advisors LLC grew its holdings in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 78.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 146,186 shares of the biopharmaceutical company's stock after purchasing an aFebruary 17, 2025 | marketbeat.comPalumbo Wealth Management LLC Buys New Position in Chimerix, Inc. (NASDAQ:CMRX)Palumbo Wealth Management LLC purchased a new position in Chimerix, Inc. (NASDAQ:CMRX - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 63,400 shares of the biopharmaceutical company's stock, valued at approxFebruary 16, 2025 | marketbeat.com Remove Ads Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRX Media Mentions By Week CMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMRX News Sentiment▼0.940.74▲Average Medical News Sentiment CMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMRX Articles This Week▼83▲CMRX Articles Average Week Remove Ads Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Apellis Pharmaceuticals News Today ACADIA Pharmaceuticals News Today MorphoSys News Today Xenon Pharmaceuticals News Today Amneal Pharmaceuticals News Today Recursion Pharmaceuticals News Today Twist Bioscience News Today Bausch Health Companies News Today NewAmsterdam Pharma News Today HUTCHMED News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMRX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
